

mersi
PT. MERSIFARMA TIRMAKU MERCUSANA
DEPARTEMEN DESIGN & PACKAGING

RANCUS 150
Size (L x W) 280 x 110 mm

Front / Back	
Type Font	
Product Name	Another Font
Myriad Pro, Bold	Arial Regular / Bold
8pt	6pt



CHECKED & APPROVED BY				
R&D		RA		
Tgl:	Tgl:	Tgl:	Tgl:	Tgl:
Staff/SPV	Manager	Staff/SPV	Manager	Dir. Prod. Dev

STANDARD SECONDARY 2026

RANCUS® 150 Tablet salut selaput 150 mg PEMERIAN Tablet cembung salut selaput warna biru, diameter 9,5 mm, penandaan atas logo mersi, penandaan bawah polos. KOMPOSISI Triap tablet salut selaput RANCUS 150 mengandung : Ranitidine HCl setara dengan Ranitidine 150 mg ZAT TAMBAHAN Pregelatinized Starch, Colloidal Silicon Dioxide, Magnesium Stearate, Microcrystalline Cellulose, Purified Water, Bahan Penyikat (Tartarazine CI 19140 E102, Lecithin, Talk, Macrogol, Brilliant Blue FCF CI 42090, Titanium Dioxide). CARA KERJA Suatu histamin antagonis reseptor H2 menghambat kerja histamin secara kompetitif pada reseptor H2 dan mengurangi sekresi asam lambung. Ranitidine diabsorbi 50% setelah pemberian oral. Konsentrasi plasma dicapai 2-3 jam setelah pemberian dosis 150 mg. Absorpsi tidak dipengaruhi secara signifikan oleh makanan dan antasida. Waktu paruh 2,5-3 jam pemberian oral. Ranitidine diekskresi melalui urin. INDIKASI - Pengobatan jangka pendek tukak usus 12 jari aktif, tukak lambung aktif, mengurangi gejala refluks esofagitis. - Terapi pemeliharaan setelah penyembuhan tukak usus 12 jari, tukak lambung. - Pengobatan keadaan hipereksesi patologis (misal : sindroma Zollinger Ellison dan mastositosis sistemik). POSOLOGI DAN CARA PEMBERIAN Posologi - Tukak usus 12 jari aktif : 150 mg, 2 kali sehari (pagi dan malam) atau 300 mg sekali sehari sesudah makan malam atau sebelum tidur, selama 4-8 minggu. - Tukak lambung aktif : 150 mg, 2 kali sehari (pagi dan malam) selama 2 minggu. - Terapi pemeliharaan pada penyembuhan tukak 12 jari dan tukak lambung. - Dewasa : 150 mg malam sebelum tidur. - Keadaan hipereksesi patologis (Zollinger Ellison, mastositosis sistemik). - Dewasa : 150 mg, 2 kali sehari dengan lama pengobatan ditentukan oleh dokter berdasarkan gejala klinis yang dapat disertai dapat ditanggalkan sesuai dengan kebutuhan masing-masing penderita. Dosis hingga 6 g sehari dapat diberikan pada penyakit yang berat. - Refluks gastro esofagitis. - Dewasa : 150 mg, 2 kali sehari. - Esofagitis erosif. - Dewasa : 150 mg, 4 kali sehari. - Pemeliharaan dan penyembuhan esofagitis erosif. - Dewasa : 150 mg, 2 kali sehari. - Dosis pada penderita gangguan fungsi ginjal : bila bersih kreatinin < 50 mL/min : 150 mg/24 hours. Bila perlu konsentrasi obat dipantau secara hati-hati setiap 12 jam atau kurang tergantung kondisi penderita. - Hemodialisis menurunkan kadar Ranitidine yang terdistribusi. Cara Pemberian Obat diberikan secara oral. KONTRAINDIKASI Penderita yang hipersensitif terhadap obat ini. EFEK SAMPING - Sakit kepala. - Susunan saraf pusat, jarang terjadi : malaise, pusing, mengantuk, insomnia, vertigo, agitasi, depresi, halusinasi. - Kardiovaskular, jarang dilaporkan : aritmia seperti takikardia, bradikardia, atrioventricular block, premature ventricular beats. - Gastrointestinal : konstipasi, mual, muntah, nyeri perut, jarang dilaporkan : pankreatitis. - Muskuloskeletal, jarang dilaporkan : artralgia dan myalgia. - Hematologik : leukopenia, granulocytopenia, trombositopenia (pada beberapa penderita), kasus jarang tetapi disertai dapat ditanggalkan sesuai dengan kebutuhan masing-masing penderita. - Endokrin : ginekomastia, impoten dan hilangnya libido pernah dilaporkan pada penderita pria. - Kulit, jarang dilaporkan : ruam, eritema multiforme, alopecia. - Lain-lain, kasus hipersensitivitas yang jarang (contoh : bronkopneumonia, demam, eosinophilia), anafilaksis, edema angioneurotik, sedikit peningkatan kadar dalam kreatinin serum. PERINGATAN DAN PERHATIAN - Umum : pada penderita yang memberikan <i>symptomatic response</i> terhadap Ranitidine, tidak menghangatkan timbulnya keganasan lambung. - Karena Ranitidine diekskresi terutama melalui ginjal, dosis Ranitidine harus disesuaikan pada penderita dengan gangguan fungsi ginjal. - Hati-hati pemberian pada gangguan fungsi hati karena Ranitidine dimetabolisme di hati. - Hindarkan pemberian pada penderita dengan riwayat porfiria akut. - Hati-hati penggunaan pada wanita menyusui. - Khasiat dan keamanan penggunaan pada anak-anak belum terbukti. - Waktu penyembuhan dan efek samping pada usia lanjut tidak sama dengan penderita usia dewasa. - Pemberian pada wanita hamil hanya jika benar-benar sangat dibutuhkan. INTERAKSI OBAT - Ranitidine tidak menghambat kerja dari sitokrom P450 dalam hati. - Pemberian bersama Warfarin dapat meningkatkan atau menurunkan waktu protrombin. OVER DOSIS Gejala-gejala overdosis antara lain, pernah dilaporkan : gangguan pencernaan akut, hipotensi, cara berjalannya yang tidak normal. Penanganan overdosis : - Induksi dengan cara dimuntahkan atau bilas lambung. - Untuk serangan : dengan cara pemberian Diazepam injeksi i.v. - Untuk bradikardia : dengan cara pemberian Atropin. - Untuk aritmia : dengan cara pemberian Lidocaine. CARA PENYIMPANAN Simpan di bawah suhu 30°C, terlindung dari cahaya. Jauhkan obat dari jangkauan anak-anak. KEMASAN DAN NOMOR REGISTRASI Dus, 10 strip @ 10 tablet salut selaput RANCUS 150, No. Reg. DKL993301517A1 Untuk pelaporan Efek Samping dan Keluhan Produk, dapat menghubungi : Tim Farmakovigilans PT. Mersifarma Email : farmakovigilans@mersifarma.com Telepon : 0818-8287-0825	RANCUS® 150 Film coated tablet 150 mg DESCRIPTION Convex film coated tablet with blue color, diameter 9,5 mm, upper initial Mersi and lower initial blank. COMPOSITION Each film coated tablet RANCUS 150 contain : Ranitidine HCl equivalent to Ranitidine 150 mg EXCIPIENTS Pregelatinized Starch, Colloidal Silicon Dioxide, Magnesium Stearate, Microcrystalline Cellulose, Purified Water, Bahan Penyikat (Tartarazine CI 19140 E102, Lecithin, Talk, Macrogol, Brilliant Blue FCF CI 42090, Titanium Dioxide). ACTIONS A histamine H2 receptor antagonists competitively inhibit the action of histamine on H2 receptors and reducing the secretion of gastric acid. Ranitidine 50% absorbed after oral administration. Peak plasma concentrations achieved 2-3 hours after dosing of 150 mg. Absorption is not significantly affected by food and antacids. The half-life 2.5-3 hours of oral administration. Ranitidine is excreted through the urine. INDICATIONS - Short-term treatment of active duodenal ulcer, active gastric ulcer, reducing the symptoms of reflux esophagitis. - Maintenance therapy after healing of duodenal ulcer and gastric ulcer. - Treatment for pathologic hypersecretion (eg, Zollinger Ellison syndrome and systemic mastocytosis). PHARMACOLOGY AND ADMINISTRATION Pharmacology - Active duodenal ulcer : 150 mg, two times daily (morning and night) or 300 mg once daily after meal or before sleep for 4-8 weeks. - Active gastric ulcer 150 mg : two times daily (morning and night) for 2 weeks. - Maintenance therapy in healing duodenal ulcer and gastric ulcer. - Adults : 150 mg before sleep. - The condition of pathologic hypersecretion (Zollinger Ellison, systemic mastocytosis). - Adults : 150 mg, two times daily with the duration of treatment is determined by the physician based on existing clinical symptoms, the dose may be increased according to the needs of each patient. Up to 6 g daily dose can be administered in severe disease. - Gastro esophagitis reflux. - Adult : 150 mg, two times daily. - Erosive esophagitis. - Adult : 150 mg, four times daily. - Maintenance and healing of erosive esophagitis. - Adult : 150 mg, two times daily. - Dose in patients with impaired renal function : when creatinine clearance < 50 mL/min : 150 mg/24 hours. If necessary the dose may be increased carefully every 12 hours or less depending on the condition of the patient. - Hemodialysis lower levels distributed Ranitidine. Administration Oral. CONTRAINDICATIONS Patients who are hypersensitive to this drug. SIDE EFFECTS - Headache. - Central nervous system, rarely occur : malaise, dizziness, drowsiness, insomnia, vertigo, agitation, depression, hallucinations. - Cardiovascular, rarely reported : arrhythmias such as tachycardia, bradycardia, atrioventricular block, premature ventricular beats. - Gastrointestinal : constipation, diarrhea, nausea, vomiting, abdominal pain, rarely reported : pancreatitis. - Musculoskeletal, rarely reported : arthralgia and myalgia. - Hematologic : leukopenia, granulocytopenia, thrombocytopenia (in some patients). Rare cases such as agranulocytopenia, pancytopenia, thrombocytopenia, aplastic anemia have been reported. - Endocrine : gynecomastia, impotence and loss of libido have been reported in male patients. - Skin, rarely reported : rash, erythema multiforme, alopecia. - Other, rare cases of hypersensitivity (eg, bronchospasm, fever, eosinophilia), anaphylaxis, angioneurotic edema, a slight increase in the levels of serum creatinine. WARNING AND PRECAUTIONS - General : in patients which gives symptomatic response to Ranitidine, does not preclude the onset of gastric malignancy. - Because Ranitidine is excreted primarily through the renal, Ranitidine dosage should be adjusted in patients with impaired renal function. - Careful administration of the impaired liver function due Ranitidine is metabolised in the liver. Avoid administration in patients with a history of acute porphyria. - Careful use in lactating women. - Efficacy and safety of use in children has not been proven. - Recovery time and side effects in elderly patients is not the same as adult. - Provision of a pregnant woman only if really desperately needed. INTERACTIONS - Ranitidine does not inhibit the action of cytochrome P450 in the liver. - Concomitant administration with Warfarin may increase or decrease the prothrombin time. OVERDOSAGE Symptoms of overdose which, have been reported : acute gastrointestinal disorders, hypotension, abnormal gait. Handling overdose : - Induction by means of regurgitated or gastric lavage. - For attack : by giving Diazepam i/v injection. - For bradycardia : by giving Atropine. - For arrhythmias : by giving Lidocaine. STORAGE Store at temperature below 30° C, protect from light. Keep out of the reach of children. PRESENTATION AND REGISTRATION NUMBER Box, 10 strips @ 10 film coated tablets RANCUS 150, Reg. No. DKL993301517A1 For reporting Side Effects and Product Complaints, please contact: PT. Mersifarma Pharmacovigilance Team Email : farmakovigilans@mersifarma.com Telephone : 0818-8287-0825 ON MEDICAL PRESCRIPTION ONLY Manufactured by : Mersifarma PT. Mersifarma TM Sukabumi-Indonesia 0000-000000-00
---	---

RANCUS® 150
Tablet salut selaput 150 mg

PEMERIAN
Tablet cembung salut selaput warna biru, diameter 9,5 mm, penandaan atas logo mersi, penandaan bawah polos.

KOMPOSISI
Tiap tablet salut selaput RANCUS 150 mengandung :
Ranitidine HCl setara dengan Ranitidine.....150 mg

ZAT TAMBAHAN
Pregelatinized Starch, Colloidal Silicon Dioxide, Magnesium Stearate, Microcrystalline Cellulose, Purified Water, Bahan Penyalut (Tartrazine CI 19140 E102, Lecithin, Talk, Macrogol, Brilliant Blue FCF CI 42090, Titanium Dioxide).

CARA KERJA
Suatu histamin antagonis reseptor H2 menghambat kerja histamin secara kompetitif pada reseptor H2 dan mengurangi sekresi asam lambung. Ranitidine diabsorbsi 50% setelah pemberian oral. Konsentrasi puncak plasma dicapai 2-3 jam setelah pemberian dosis 150 mg. Absorbsi tidak dipengaruhi secara signifikan oleh makanan dan antasida. Waktu paruh 2,5-3 jam pemberian oral. Ranitidine diekskresi melalui urin.

INDIKASI
- Pengobatan jangka pendek tukak usus 12 jari aktif, tukak lambung aktif, mengurangi gejala refluks esofagitis.
- Terapi pemeliharaan setelah penyembuhan tukak usus 12 jari, tukak lambung.
- Pengobatan keadaan hipersekresi patologis (misal : sindroma Zollinger Ellison dan mastositosis sistemik).

POSOLOGI DAN CARA PEMBERIAN
Posologi
- Tukak usus 12 jari aktif : 150 mg, 2 kali sehari (pagi dan malam) atau 300 mg sekali sehari sesudah makan malam atau sebelum tidur, selama 4-8 minggu.
- Tukak lambung aktif : 150 mg, 2 kali sehari (pagi dan malam) selama 2 minggu.
- Terapi pemeliharaan pada penyembuhan tukak 12 jari dan tukak lambung.
Dewasa : 150 mg malam sebelum tidur.
- Keadaan hipersekresi patologis (Zollinger Ellison, mastositosis sistemik).
Dewasa : 150 mg, 2 kali sehari dengan lama pengobatan ditentukan oleh dokter berdasarkan gejala klinik yang ada, dosis dapat ditingkatkan sesuai dengan kebutuhan masing-masing penderita. Dosis hingga 6 g sehari dapat diberikan pada penyakit yang berat.
- Refluks gastro esofagitis.
Dewasa : 150 mg, 2 kali sehari.
- Esofagitis erosif.
Dewasa : 150 mg, 4 kali sehari.
- Pemeliharaan dan penyembuhan esofagitis erosif.
Dewasa : 150 mg, 2 kali sehari.
- Dosis pada penderita gangguan fungsi ginjal : bila bersihan kreatinin < 50 mL/minit : 150 mg/24 jam. Bila perlu dosis dapat ditingkatkan secara hati-hati setiap 12 jam atau kurang tergantung kondisi penderita.
- Hemodialisis menurunkan kadar Ranitidine yang terdistribusi.
Cara Pemberian
Obat diberikan secara oral.

KONTRAINDIKASI
Penderita yang hipersensitif terhadap obat ini.

EFEK SAMPING
- Sakit kepala.
- Susunan saraf pusat, jarang terjadi : malaise, pusing, mengantuk, insomnia, vertigo, agitasi, depresi, halusinasi.
- Kardiovaskular, jarang dilaporkan : aritmia seperti takikardia, bradikardia, *atrioventricular block, premature ventricular beats*.
- Gastrointestinal : konstipasi, diare, mual, muntah, nyeri perut, jarang dilaporkan : pankreatitis.
- Muskuloskeletal, jarang dilaporkan : artralgia dan mialgia.
- Hematologi : leukopenia, granulositopenia, trombositopenia (pada beberapa penderita). Kasus jarang terjadi seperti agranulositopenia, pansitopenia, trombositopenia, anemia aplastik pernah dilaporkan.
- Endokrin : ginekomastia, impoten dan hilangnya libido pernah dilaporakan pada penderita pria.
- Kulit, jarang dilaporkan : ruam, eritema multiforme, alopecia.
- Lain-lain, kasus hipersensitivitas yang jarang (contoh : bronkospasma, demam, eosinofilia), anafilaksis, edema angioneurotik, sedikit peningkatan kadar dalam kreatinin serum.

PERINGATAN DAN PERHATIAN
- Umum : pada penderita yang memberikan *symptomatic response* terhadap Ranitidine, tidak menghalangi timbulnya keganasan lambung.
- Karena Ranitidine diekskresi terutama melalui ginjal, dosis Ranitidine harus disesuaikan pada penderita dengan gangguan fungsi ginjal.
- Hati-hati pemberian pada gangguan fungsi hati karena Ranitidine dimetabolisme di hati.
- Hindarkan pemberian pada penderita dengan riwayat porfiria akut.
- Hati-hati penggunaan pada wanita menyusui.
- Khasiat dan keamanan penggunaan pada anak-anak belum terbukti.
- Waktu penyembuhan dan efek samping pada usia lanjut tidak sama dengan penderita usia dewasa.
- Pemberian pada wanita hamil hanya jika benar-benar sangat dibutuhkan.

INTERAKSI OBAT
- Ranitidine tidak menghambat kerja dari sitokrom P450 dalam hati.
- Pemberian bersama Warfarin dapat meningkatkan atau menurunkan waktu protrombin.

OVER DOSIS
Gejala-gejala overdosis antara lain, pernah dilaporkan : gangguan pencernaan akut, hipotensi, cara berjalan yang tidak normal.
Penanganan overdosis :
- Induksi dengan cara dimuntahkan atau bilas lambung.
- Untuk serangan : dengan cara pemberian Diazepam injeksi i.v.
- Untuk bradikardia : dengan cara pemberian Atropin.
- Untuk aritmia : dengan cara pemberian Lidokain.

CARA PENYIMPANAN
Simpan di bawah suhu 30°C, terlindung dari cahaya.
Jauhkan obat dari jangkauan anak-anak.

KEMASAN DAN NOMOR REGISTRASI
Dus, 10 strip @ 10 tablet salut selaput RANCUS 150, No. Reg. DKL9933301517A1

Untuk pelaporan Efek Samping dan Keluhan Produk, dapat menghubungi :
Tim Farmakovigilans PT. Mersifarma
Email : farmakovigilans@mersifarma.com
Telepon : 0818-8287-0825

HARUS DENGAN RESEP DOKTER

Diproduksi oleh :

 **mersi**
PT. Mersifarma TM
Sukabumi-Indonesia

RANCUS® 150
Film coated tablet 150 mg

DESCRIPTION
Convex film coated tablet with blue color, diameter 9,5 mm, upper initial Mersi and lower initial blank.

COMPOSITION
Each film coated tablet RANCUS 150 contain :
Ranitidine HCl equivalent to Ranitidine.....150 mg

EXCIPIENTS
Pregelatinized Starch, Colloidal Silicon Dioxide, Magnesium Stearate, Microcrystalline Cellulose, Purified Water, Bahan Penyalut (Tartrazine CI 19140 E102, Lecithin, Talk, Macrogol, Brilliant Blue FCF CI 42090, Titanium Dioxide).

ACTIONS
A histamine H2 receptor antagonists competitively inhibit the action of histamine on H2 receptors and reducing the secretion of gastric acid. Ranitidine 50% absorbed after oral administration. Peak plasma concentrations achieved 2-3 hours after dosing of 150 mg. Absorption is not significantly affected by food and antacids. The half-life 2.5-3 hours of oral administration. Ranitidine is excreted through the urine.

INDICATIONS
- Short-term treatment of active duodenal ulcer, active gastric ulcer, reducing the symptoms of reflux esophagitis.
- Maintenance therapy after healing of duodenal ulcer, gastric ulcer.
- Treatment for pathologic hypersecretion (eg, Zollinger Ellison syndrome and systemic mastocytosis).

POSODOLOGY AND ADMINSTRATION
Posology
- Active duodenal ulcer : 150 mg, two times daily (morning and night) or 300 mg once daily after meal or before sleep, for 4-8 weeks.
- Active gastric ulcer 150 mg : two times daily (morning and night) for 2 weeks.
- Maintenance therapy in healing duodenal ulcer and gastric ulcer.
Adults : 150 mg before sleep.
- The condition of pathologic hypersecretion (Zollinger Ellison, systemic mastocytosis).
Adults : 150 mg, two times daily with the duration of treatment is determined by the physician based on existing clinical symptoms, the dose may be increased according to the needs of each patient. Up to 6 g daily dose can be administered in severe disease.
- Gastro esophagitis reflux.
Adult : 150 mg, two times daily.
- Erosive esophagitis.
Adult : 150 mg, four times daily.
- Maintenance and healing of erosive esophagitis.
Adult : 150 mg, two times daily.
- Dose in patients with impaired renal function : when creatinine clearance < 50 mL/min : 150 mg/24 hours. If necessary the dose may be increased carefully every 12 hours or less depending on the condition of the patient.
- Hemodialysis lower levels distributed Ranitidine.
Administration
Oral.

CONTRAINDICATIONS
Patients who are hypersensitive to this drug.

SIDE EFFECTS
- Headache.
- Central nervous system, rarely occur : malaise, dizziness, drowsiness, insomnia, vertigo, agitation, depression, hallucinations.
- Cardiovascular, rarely reported : arrhythmias such as tachycardia, bradycardia, atrioventricular block, premature ventricular beats.
- Gastrointestinal : constipation, diarrhea, nausea, vomiting, abdominal pain, rarely reported : pancreatitis.
- Musculoskeletal, rarely reported : arthralgia and myalgia.
- Hematologic : leukopenia, granulocytopenia, thrombocytopenia (in some patients). Rare cases such as agranulocytopenia, pancytopenia, thrombocytopenia, aplastic anemia have been reported.
- Endocrine : gynecomastia, impotence and loss of libido have been reported in male patients.
- Skin, rarely reported : rash, erythema multiforme, alopecia.
- Other, rare cases of hypersensitivity (eg, bronchospasm, fever, eosinophilia), anaphylaxis, angioneurotic edema, a slight increase in the levels of serum creatinine.

WARNING AND PRECAUTIONS
- General : in patients which gives symptomatic response to Ranitidine, does not preclude the onset of gastric malignancy.
- Because Ranitidine is excreted primarily through the renal, Ranitidine dosage should be adjusted in patients with impaired renal function.
- Careful administration of the impaired liver function due Ranitidine is metabolised in the liver.
- Avoid administration in patients with a history of acute porphyria.
- Careful use in lactating women.
- Efficacy and safety of use in children has not been proven.
- Recovery time and side effects in elderly patients is not the same as adult.
- Provision of a pregnant woman only if really desperately needed.

INTERACTIONS
- Ranitidine does not inhibit the action of cytochrome P450 in the liver.
- Concomitant administration with Warfarin may increase or decrease the prothrombin time.

OVERDOSAGE
Symptoms of overdosage which, have been reported : acute gastrointestinal disorders, hypotension, abnormal gait.
Handling overdosage :
- Induction by means of regurgitated or gastric lavage.
- For attack : by giving Diazepam i.v injection.
- For bradycardia : by giving Atropine.
- For arrhythmias : by giving of Lidocaine.

STORAGE
Store at temperature below 30° C, protect from light.
Keep out of the reach of children.

PRESENTATION AND REGISTRATION NUMBER
Box, 10 strips @ 10 film coated tablets RANCUS 150, Reg. No. DKL9933301517A1

For reporting Side Effects and Product Complaints, please contact:
PT. Mersifarma Pharmacovigilance Team
Email : farmakovigilans@mersifarma.com
Telephone : 0818-8287-0825

ON MEDICAL PRESCRIPTION ONLY

Manufactured by :

 **mersi**
PT. Mersifarma TM
Sukabumi-Indonesia

0000-000000-00